ALKS Alkermes plc - Ordinary Shares

55.46
+0  (0%)
Previous Close 55.46
Open 54.76
Price To book 6.96
Market Cap 8.43B
Shares 151,970,000
Volume 743,069
Short Ratio 6.73
Av. Daily Volume 1,189,350

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 5 2015. sNDA filed for 2-month option August 8 2016. PDUFA date estimate June 8, 2017.
Aristada
Schizophrenia
Approved October 5 2015. sNDA filing due 2H 2016
Aristada
Schizophrenia
Phase 3 trial to be initiated 2017 with data and NDA filing due 2018. BPC estimate of data mid-2018.
ALKS 8700
Multiple sclerosis (MS)
Phase 3 initated September 2015. Data due 1H 2017.
ALKS 6428
Opioid dependence
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. NDA to be filed 2017.
ALKS 5461
Major depressive disorder
Pivotal trials initiated December 2015 and February 2016. Four week efficacy data due YE 2017. Six month weight data mid-2018.
ALKS 3831 - ENLIGHTEN-1 and ENLIGHTEN-2
Schizophrenia

Latest News

  1. Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More
  2. Blog Coverage Valeant Sells-Off Its Skin Care Brands to L'Oreal
  3. Top Biotech Picks: "The Strong Will Survive And Thrive"
  4. Alkermes Plc – Value Analysis (NASDAQ:ALKS) : January 5, 2017
  5. Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : January 4, 2017
  6. Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare Conference
  7. Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare Conference
  8. Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare Conference
  9. ETFs with exposure to Alkermes Plc : December 21, 2016
  10. Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?
  11. CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD
  12. ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers
  13. CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501
  14. Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?
  15. Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election
  16. Drug pricing pressure
  17. ETF’s with exposure to Alkermes Plc : November 10, 2016
  18. Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference
  19. Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference
  20. Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference

SEC Filings

  1. UPLOAD [Cover] - SEC-generated letter
  2. S-8 - Securities to be offered to employees in employee benefit plans 162039374
  3. 8-K - Current report 162031504
  4. CORRESP [Cover] - Correspondence
  5. UPLOAD [Cover] - SEC-generated letter
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161966352
  7. 8-K - Current report 161966277
  8. 8-K - Current report 161944469
  9. 8-K - Current report 161935338
  10. CORRESP [Cover] - Correspondence